Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.375p -6.12% 5.75p 5.50p 6.00p 6.125p 5.75p 6.125p 108,761 11:24:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 4.30

N4 Pharma (N4P) Latest News

More N4 Pharma News
N4 Pharma Takeover Rumours

N4 Pharma (N4P) Share Charts

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart

Intraday N4 Pharma Chart

Intraday N4 Pharma Chart

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
18/10/201712:42N4 Pharma - Making good drugs better.576
15/5/201712:54N4 Pharma54

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
14:15:085.6010,600593.07O
12:35:205.6023,1611,295.86O
10:24:176.0050,0003,000.00O
07:44:196.0025,0001,500.00O
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

DateSubject
18/10/2017
09:20
N4 Pharma Daily Update: N4 Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 6.13p.
N4 Pharma has a 4 week average price of 5.25p and a 12 week average price of 4.75p.
The 1 year high share price is 12.38p while the 1 year low share price is currently 4.75p.
There are currently 74,714,285 shares in issue and the average daily traded volume is 536,093 shares. The market capitalisation of N4 Pharma is £4,296,071.39.
01/9/2017
09:24
top tips: IMMUPHARMA (IMM) Potential blockbuster Lupuzor Phase III results due Q1 2018. Only other similar drug Benlysta was bought out from HGSi by GSK in 2012 for $3.6 billion for 50% stake valuing Benlysta around $7 billion (and IMM's Lupuzor appears to be safer and more efficaceous than Benlysta). $7 billion buyout of IMM gives £39.70 share price against current 49p, or 80 bagger !!! Potential blockbuster Lupuzor has 'Fast Track' and 'SPA' status from US FDA, so could market launched in 2018. Tim McCarthy (IMM's Chairman) 14/3/2017: "There's going to be a fantastic return on investment for anybody who invests in ImmuPharma...This (Lupuzor) is going to be a multi-billion dollar drug, its as simple as that...This will absolutely be a multi-billion dollar drug." 4 min 40 sec. hTTps://www.youtube.com/watch?v=M5Af_uSSXTM
03/8/2017
16:11
biggest bill: Flexton, only ten minutes ago you claimed that you had correctly predicted that the share price here would go under 5p. This claim was made only 2 days ago. Are you having problems remembering what you wrote?
03/8/2017
16:00
biggest bill: Flexton, your first post on N4P was on 1/8/17 and you have certainly not made a correct prediction about the share price here. Your many subsequent posts here have been ridiculous to put it mildly. For somebody who claims to hold shares here (which I don't believe for a minute), your behaviour has been bizarre.
01/8/2017
12:39
zebbo: "Inherent value here is way above the current share price". Value is way way above current share price and then some. I am going to partake in the 1000% ++ rise that is expected over the next few years. Get in early and then place in bottom draw, thats how real money is made Side note - Also not sure who wrote the last RNS as it was poorly worded and just left a load of questions unanswered and failed to highlight the commercial aspects
01/8/2017
11:34
square root: It looks for once if my timing has been good. The inherent value here is way above the current share price.
27/7/2017
23:11
bones: For those clearly demoralised investors who can now only see downsides (even to today's progress announcement!) due to the depressed share price should remind themselves of the array of IP and future potential that N4P possesses. Not only that but the scaremongerers saying that the company will always be seeking cash have to remember that there are warrant holders who may put in £1.8m at 8p per share over the next two years plus the company will receive plenty of grants from UK bodies like Innovate UK that helps small companies with promising developments in science. No-one is saying that, in the future, no further funds will be needed from the market but that is common for pharma cos. There are companies on Nasdaq that only earn from milestones from large pharma yet are valued in billions of dollars. Perhaps these Youtube clips might help refocus on why you are invested (and not trading) and then forget about daily movements and market swings. https://www.youtube.com/watch?v=9IvlyamyPzc https://www.youtube.com/watch?v=3DxrR6Cxd4E https://www.youtube.com/watch?v=3T14Jk2ETgk N4P is today valued in total at less than £5m. Crazy huh?
03/7/2017
18:23
bdog51: I'm with you on that Flash. When the direction of travel reverses, the N4P share price can really motor. Bargain price down at these low levels right now. Just takes a bit of news flow to change the tide.
17/6/2017
17:04
bones: Zebbo, I note that Pfizer article was published over two months ago so doesn't seem to have harmed N4P price since then.You say N4P could be in the right place at the right time but do you not think Pfizer could be a giant to be fighting here?I know that N4P are aware that, in any generic post-patent space, competition will be plentiful but that there should be room for everyone who has a decent improvement. Question for me is would Pfizer look to the likes of N4P to licence from or would it use its clout to do everything itself and squeeze smaller competitors?I do not have the answers, by the way :)
30/5/2017
12:40
darkinbad: Ch1rp, a double top is a technical indicator. The share price has established resistance at 9.625 so if the share price approaches it and fails to push through, pulling back with a lower end of day price, it then effectively establishes two consecutive high points at the resistance level - 'a double top'. If one does form, the share price may pull back further, possibly going to the recently established support at 8.25.
18/5/2017
12:50
someuwin: CEO owns 17% of the equity here. This is almost entirely from his own purchases on the market when this was ONZ (see repeated Holdings RNSs last year). Furthermore his consideration shares resulting from the new N4P listing are deferred until the N4P share price has been over 15p for 10 consecutive days. ...I don't think it will be too long before that situation occurs.
N4 Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171018 22:25:45